Related Experiment Video

Updated: Jul 6, 2025

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
07:14

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

Published on: May 31, 2016

14.7K

Corrigendum: Revisiting the L-dopa response as a predictor of motor outcomes after deep brain stimulation in

Zhengyu Lin1,2, Xiaoxiao Zhang1,2, Linbin Wang1,2

  • 1Department of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Frontiers in Human Neuroscience
|January 1, 2024
PubMed

Abstract:

[This corrects the article DOI: 10.3389/fnhum.2021.604433.].

Keywords:
L-dopa challenge testParkinson's diseasedeep brain stimulationglobus pallidus internasubthalamic nucleus

More Related Videos

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.5K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.8K

Related Experiment Videos

Last Updated: Jul 6, 2025

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
07:14

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

Published on: May 31, 2016

14.7K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.5K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.8K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

273
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
273
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

553
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
553
Neural Regulation01:37

Neural Regulation

39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K

Articles linked to this work by shared authors, journal, and citation graph.

Effects of globus pallidus internus deep brain stimulation on freezing of gait in Parkinson's disease: a prospective short-term single-arm study.

Frontiers in aging neuroscience·2026

Stepwise engagement of cingulate ensembles underlies motivational decline in chronic pain.

Neuron·2026

XR-integrated brain-computer interfaces for augmentative and alternative communication: a systematic review.

Frontiers in human neuroscience·2026

Subthalamic spatio-spectral-connectivity of psychiatric symptoms in Parkinson's disease.

Brain : a journal of neurology·2026

Remote programming versus standard in-person programming following deep brain stimulation in patients with Parkinson's disease: a randomised controlled trial.

EClinicalMedicine·2026

Adaptive shifts in amygdala-hippocampal theta coupling govern aversive learning and extinction.

Nature communications·2026

Investigation of human defence responses in a virtual reality environment: an EEG study.

Frontiers in human neuroscience·2026

Exploring partially shared valuation-related neural responses between abstract desirability and food incentive evaluation.

Frontiers in human neuroscience·2026

From metric to model: a five-stage pipeline for building and sustaining valid AI predictive systems in consumer neuroscience.

Frontiers in human neuroscience·2026

Vision In SyndrOmic Neurodevelopmental disorders-15q (VISiON-15q) study: eye tracking to supplement clinical examination for detection of cerebral/cortical visual impairment in children with Angelman and Duplication of 15q Syndromes.

Frontiers in human neuroscience·2026

Combined assessment of FLAIR vascular hyperintensities and cortical venous outflow for outcome prediction in acute middle cerebral artery occlusion.

Frontiers in human neuroscience·2026

Trust your gut: the neuro-gastroenteric mechanics of prediction and expectation.

Frontiers in human neuroscience·2026

Handling missed dose of riluzole by population pharmacokinetic model informed remedial regimen.

Frontiers in pharmacology·2026

PHARMWATCH: A Proposed Multilayer Pharmacogenomics Framework for Contextual Star Allele Interpretation.

Clinical and translational science·2026

DRAMP 5.0: an update integrating sequence and structure in a novel FASTS format for AI-driven design of antimicrobial peptides.

Nucleic acids research·2026

Reprocessing Mass Spectra from Therapeutic Drug Monitoring to Unveil Proton Pump Inhibitor Use and Quantify Phenoconversion of Escitalopram Metabolism in CYP2C19-Genotyped Patients.

Clinical pharmacology and therapeutics·2026

Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Melanin-Concentrating Hormone Receptor-1 Antagonist RGH-706 in Healthy and Overweight or Obese Men.

Diabetes, obesity & metabolism·2026

Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity.

Diabetes, obesity & metabolism·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us